Skip to main content

Table 3 Baseline predictors of “good responder” before IC CD34+ therapy for EnD-CAD

From: Baseline factors identified for the prediction of good responders in patients with end-stage diffuse coronary artery disease undergoing intracoronary CD34+ cell therapy

LVEF improvement ≥ 7.0%

Univariate analysis

Multivariate analysis

Variables

OR

95% CI

P value

OR

95% CI

P value

Baseline characteristics

 Age per year

1.027

0.967–1.090

0.389

   

 Age ≥ 65 years

1.524

0.571–4.065

0.400

   

 Male sex

0.301

0.082–1.106

0.071

0.028

0.003–0.261

0.002

 Body mass index

0.985

0.879–1.104

0.799

   

 Former smoker

2.857

1.024–7.970

0.045

8.898

1.891–41.858

0.006

 Diabetes mellitus

1.102

0.357–3.405

0.866

   

 Atherosclerotic risk factor*

n/a

n/a

n/a

   

 Old stroke or old MI

0.706

0.263–1.893

0.489

   

 Chronic hepatitis B or C

0.267

0.028–2.533

0.250

   

 History of CABG

0.406

0.138–1.194

0.101

   

 Left main involvement

0.583

0.195–1.747

0.335

   

 CTO at LAD

0.962

0.362–2.560

0.939

   

 Leukocyte count

0.765

0.576–1.018

0.066

0.860

0.632–1.170

0.077

 Hemoglobin

0.950

0.729–1.237

0.702

   

 Serum creatinine

0.776

0.292–2.060

0.610

   

 eGFR

1.003

0.981–1.027

0.766

   

 Total Cholesterol

1.004

0.992–1.016

0.528

   

 Beta blocker

n/a

n/a

n/a

   

 RAS inhibitor

0.424

0.111–1.622

0.210

   

 Lipid lowering agent

0.800

0.278–2.299

0.679

   

Presentation and exams at baseline

 CCS angina score ≥ 3

0.232

0.082–0.658

0.006

0.138

0.033–0.576

0.007

 NYHA Fc of dyspnea ≥ 3

0.664

0.220–2.009

0.468

   

 Endothelial dysfunction

0.593

0.202–1.738

0.341

   

 CPET-METs

0.732

0.429–1.246

0.250

   

 CMR LVEF

1.022

0.987–1.059

0.225

   

 Angiogenesis score ≥ 2

2.250

0.816–6.207

0.117

   

 3D echo LVEF

0.968

0.923–1.106

0.187

   

 3D echo LVEF  ≥ 50%

0.682

0.250–1.863

0.456

   

 3D echo LVEF ≤ 40%

2.667

0.605–11.756

0.195

   

Baseline echocardiography

 LA diameter

1.035

0.944–1.136

0.461

   

 LVEDD

0.999

0.943–1.059

0.980

   

 2D echo LVEF

0.995

0.958–1.033

0.786

   

 Grade 2 or 3 diast. dysfxn

0.240

0.081–0.710

0.010

0.104

0.022–0.505

0.005

 TVPG

1.017

0.972–1.064

0.469

   

 Moderate to severe MR

1.550

0.376–6.390

0.544

   

 3D echo LVEDV

0.999

0.980–1.017

0.894

   

 Systolic dyssynchrony index

1.028

0.955–1.106

0.466

   
  1. Notes: Abbreviation: IC intracoronary, EnD-CAD end-stage diffuse coronary artery disease, LVEF left ventricular ejection fraction, OR odds ratio, CI confidence interval, n/a not applicable, MI myocardial infarction, CABG coronary artery bypass grafting surgery, CTO chronic total occlusion, LAD left anterior descending artery, eGFR estimated glomerular filtration rate, RAS renin-angiotensin system, CCS Canadian Cardiovascular Society, NYHA Fc New York Heart Association functional classification, CPET cardiopulmonary exercise testing, MET metabolic equivalent of task, CMR Cardiovascular magnetic resonance imaging, LVEF left ventricular ejection fraction, 3D echo three-dimensional echocardiography, LA left atrium, LVEDD left ventricular end-diastolic diameter, 2D echo two-dimensional echocardiography, diast. dysfxn diastolic dysfunction, TVPG trans-tricuspid valve pressure gradient, MR mitral regurgitation, LVEDV left ventricular end-diastolic volume
  2. *Atherosclerotic risk factors indicate hypertension, diabetes, or dyslipidemia; data was not available because all EnD-CAD patients had at least one of the atherosclerotic risk factors
Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512